Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Labcorp (LH) reported strong Q4 and full-year 2024 results, with Q4 revenue reaching $3.33 billion (up 9.8% YoY) and full-year revenue of $13.01 billion (up 7.0% YoY). The company's Q4 diluted EPS improved to $1.70 from $(1.95) last year, while adjusted EPS increased to $3.45 from $3.30.
Free cash flow showed significant improvement, with Q4 at $665.1 million (up from $412.4 million) and full-year at $1.10 billion (up from $748.7 million). The company completed 10 transactions in 2024 and launched new innovative tests in specialty areas.
For 2025, Labcorp projects revenue between $13.88-14.05 billion (7.4% growth at midpoint), adjusted EPS of $15.60-16.40 (9.8% growth at midpoint), and free cash flow of $1.10-1.25 billion (7.2% growth at midpoint).
Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, January 14, at 3:45 p.m. Pacific Time.
Interested parties can access a live audio webcast of the discussion through Labcorp's Investor Relations website at ir.Labcorp.com. The session will also be archived for future viewing.
Labcorp (NYSE: LH) has announced a quarterly cash dividend of $0.72 per share of common stock. The dividend will be distributed on March 12, 2025, to stockholders recorded as of the close of business on February 27, 2025. This announcement comes from the global leader in innovative and comprehensive laboratory services, following a declaration by its Board of Directors.
Labcorp (NYSE: LH) has announced it will release its fourth quarter 2024 financial results before market opens on February 6, 2025. The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the results.
The earnings release and financial information will be available on Labcorp's Investor Relations website. Participants can join the listen-only webcast and conference call through registration, with recommended arrival 10 minutes before start time. A replay of the webcast will be accessible approximately two hours after the event and remain available until January 24, 2026.
Geneoscopy has successfully closed a $105 million Series C funding round, led by Bio-Rad Laboratories (NYSE: BIO). The funding will support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease.
The investment round included participation from notable investors including Petrichor, Labcorp, Morningside Ventures, and others. Geneoscopy's technology combines RNA isolation from stool samples with Bio-Rad's Droplet Digital™ PCR technology for effective cancer screening. Through a partnership with Labcorp, ColoSense will be made widely available to healthcare providers.
This funding follows FDA approval of ColoSense and aims to address the rising incidence of colorectal cancer, particularly among people under 50. The test offers a non-invasive alternative to traditional colonoscopies, potentially increasing screening accessibility for millions of eligible individuals who currently avoid testing.
Labcorp (NYSE: LH) has launched a new commercial H5 bird flu molecular test in the United States to diagnose human infections with H5N1 virus. The test development, supported by the CDC, comes amid a multistate outbreak affecting poultry and dairy cows, with recent human cases reported in dairy and poultry workers. Healthcare providers can now order the test for suspected cases, collecting nasopharyngeal swab specimens for PCR analysis.
While current public health risk remains low, the test enhances testing infrastructure and supports public health preparedness. The CDC is monitoring human cases, and the USDA is conducting surveillance of milk supply and dairy herds. This initiative follows Labcorp's previous collaborations with CDC on testing for emerging viruses like Zika, COVID-19, and mpox.
Outcomes4Me and Labcorp will present findings from their joint biomarker awareness study at the 2024 San Antonio Breast Cancer Symposium. The research focused on HER2-low awareness in metastatic breast cancer patients. The study revealed that 41.9% of patients with known HER2 status were not well-aware of HER2-low classification, and 51.3% of HER2-negative patients didn't recall discussing HER2-low with their oncologists.
Through a digital education campaign including discussion guides and webinars, the initiative showed promising results: 60.9% of patients with unknown HER2 status felt likely to discuss testing with their oncologist after engaging with the educational content. The study demonstrates how digital patient education can effectively increase biomarker awareness and encourage patient-provider discussions about testing.
Labcorp (NYSE: LH) announced that Executive Vice President and CFO Glenn Eisenberg will retire, with Julia Wang appointed as the new CFO effective December 2, 2024. Eisenberg will remain as Special Advisor to the CEO through April 2025. During Eisenberg's 10-year tenure, Labcorp doubled its revenues, completed approximately 100 acquisitions worth $11 billion, and returned over $6 billion to shareholders through repurchases and dividends. Wang joins from BeiGene, where she served as CFO and was key in driving business transformations through growth acceleration and operational efficiency.
Praia Health has secured a strategic investment from Labcorp Venture Fund and announced a collaboration to enhance patient lab ordering experiences. The partnership will integrate Praia Health's technology with Labcorp's testing capabilities to streamline lab testing processes. Praia's platform will provide personalized notifications within health systems' mobile apps, allowing patients to easily schedule lab tests and locate appropriate Labcorp facilities. The collaboration will initially launch at Providence's Puget Sound location, with plans to expand to other healthcare systems nationwide.
Labcorp (NYSE: LH) reported strong Q3 2024 results with revenue increasing 7.4% to $3.28 billion from $3.06 billion last year. Adjusted EPS rose to $3.50 from $3.38, while diluted EPS decreased to $2.00 from $2.11. The company updated its full-year 2024 guidance with revenue growth of 6.6% to 7.3% and adjusted EPS range of $14.30 to $14.70. During the quarter, Labcorp announced three new acquisitions/lab management agreements and completed two acquisitions, including select assets of BioReference Health and Invitae. Free cash flow was $162 million, down from $171 million in the previous year.